A new study found severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was associated with the rapid growth of plaque in the coronary arteries and an increased risk of cardiovascular ...

COVID-19 accelerates the progression of atherosclerotic plaques, increasing coronary inflammation and the risk of high-risk ...

Bonus Biogroup has received FDA approval for an IND application to conduct a Phase III clinical trial of a drug designed to treat acute respiratory distress syndrome (ARDS), especially in severe COVID ...

COVID-19 was associated with more severe disease outcomes than influenza or RSV during the 2022 to 2023 season.

On this day in 2020, the World Health Organization (WHO) named a disease spreading from Wuhan, China, COVID-19. On Feb. 11, ...

The following is a summary of “Plasma Lipopolysaccharide-Binding Protein (LBP) Is Induced in Critically Ill Females with Gram ...

Seven rheumatology researchers have authored a paper questioning the utility of the 2024 National Academies’ broad definition of long COVID.

while development of new PCS symptoms among those initially recovered was associated with an intercurrent secondary severe acute respiratory syndrome coronavirus 2 infection and educational status.

COVID-19. The coronaviruses that cause COVID, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS) have similar symptoms. They include headache, nausea ...

Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.03 and ...

Coronary artery lesions in patients with SARS-CoV-2 infection more likely to become high-risk plaques. HealthDay News — Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is ...